Lomitapide (Juxtapid® in US and Lojuxta® in Europe) is the first developed inhibitor of the microsomal triglyceride transfer protein (MTP) approved as a novel drug for the management of homozygous familial hypercholesterolemia (HoFH). It acts by binding directly and selectively to MTP thus decreasing the assembly and secretion of the apo-B containing lipoproteins both in the liver and in the intestine.
Giammanco, A., Cefalù, A.B., Noto, D., & Averna, M. (2020). Therapeutic options for homozygous familial hypercholesterolemia: the role of Lomitapide. CURRENT MEDICINAL CHEMISTRY, 27(23), 3773-3783.
Data di pubblicazione: | 2020 |
Titolo: | Therapeutic options for homozygous familial hypercholesterolemia: the role of Lomitapide |
Autori: | |
Citazione: | Giammanco, A., Cefalù, A.B., Noto, D., & Averna, M. (2020). Therapeutic options for homozygous familial hypercholesterolemia: the role of Lomitapide. CURRENT MEDICINAL CHEMISTRY, 27(23), 3773-3783. |
Rivista: | |
Digital Object Identifier (DOI): | http://dx.doi.org/10.2174/0929867326666190121120735 |
Abstract: | Lomitapide (Juxtapid® in US and Lojuxta® in Europe) is the first developed inhibitor of the microsomal triglyceride transfer protein (MTP) approved as a novel drug for the management of homozygous familial hypercholesterolemia (HoFH). It acts by binding directly and selectively to MTP thus decreasing the assembly and secretion of the apo-B containing lipoproteins both in the liver and in the intestine. |
Appare nelle tipologie: | 1.01 Articolo in rivista |
File in questo prodotto:
File | Descrizione | Tipologia | Licenza | |
---|---|---|---|---|
Therapeutic Options for Homozygous Familial Hypercholesterolemia_correted proof.pdf | Pre-print | Administrator Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.